Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhythm Pharmaceuticals, Inc.

http://www.rhythmtx.com

Latest From Rhythm Pharmaceuticals, Inc.

Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization

Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.

Financing StartUps and SMEs

Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM

Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.

South Korea Research and Development Strategies

Alexion's R&D Plans At Increased Pace With Rhythm Voucher

After last month’s news of its proposed acquisition by AstraZeneca, Alexion Pharmaceuticals has bought a priority review voucher from Rhythm Pharmaceuticals, which would speed one of its development projects towards the marketplace.

Business Strategies Rare Diseases

Plenty Of Action On EU Accelerated Assessment Front

A number of companies have sought to convince the European Medicine Agency that their drug merits a fast-track regulatory review.

Europe Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Rhythm Metabolic, Inc.
UsernamePublicRestriction

Register